143 related articles for article (PubMed ID: 1907566)
1. Two years treatment with almitrine bismesylate in patients with hypoxic chronic obstructive airways disease.
Bardsley PA; Howard P; DeBacker W; Vermeire P; Mairesse M; Ledent C; Radermecker M; Bury T; Ansquer J
Eur Respir J; 1991 Mar; 4(3):308-10. PubMed ID: 1907566
[TBL] [Abstract][Full Text] [Related]
2. Almitrine bismesylate: a long-term placebo-controlled double-blind study in COAD--Vectarion International Multicentre Study Group.
Voisin C; Howard P; Ansquer JC
Bull Eur Physiopathol Respir; 1987 Aug; 23 Suppl 11():169s-182s. PubMed ID: 3318971
[TBL] [Abstract][Full Text] [Related]
3. Sequential treatment with low dose almitrine bismesylate in hypoxaemic chronic obstructive airways disease.
Bardsley PA; Howard P; Tang O; Empey D; Harrison B; Peake MD; O'Reilly J; Riordan JF; Wilkinson J; Arnaud F
Eur Respir J; 1992 Oct; 5(9):1054-61. PubMed ID: 1426214
[TBL] [Abstract][Full Text] [Related]
4. One year treatment with almitrine improves hypoxaemia but does not increase pulmonary artery pressure in COPD patients.
Weitzenblum E; Schrijen F; Apprill M; Prefaut C; Yernault JC
Eur Respir J; 1991 Nov; 4(10):1215-22. PubMed ID: 1804669
[TBL] [Abstract][Full Text] [Related]
5. Oral almitrine in treatment of acute respiratory failure and cor pulmonale in patients with an exacerbation of chronic obstructive airways disease.
Bardsley PA; Tweney J; Morgan N; Howard P
Thorax; 1991 Jul; 46(7):493-8. PubMed ID: 1908604
[TBL] [Abstract][Full Text] [Related]
6. Effects of almitrine bismesylate on arterial blood gases in patients with chronic obstructive pulmonary disease and moderate hypoxaemia: a multicentre, randomised, double-blind, placebo-controlled study.
Górecka D; Sliwiński P; Pałasiewicz G; Pachocki R; Zieliński J;
Respiration; 2003; 70(3):275-83. PubMed ID: 12915747
[TBL] [Abstract][Full Text] [Related]
7. Low-dose almitrine bismesylate in the treatment of hypoxemia due to chronic obstructive pulmonary disease.
Winkelmann BR; Kullmer TH; Kneissl DG; Trenk D; Kronenberger H
Chest; 1994 May; 105(5):1383-91. PubMed ID: 8181324
[TBL] [Abstract][Full Text] [Related]
8. [Almitrine bismesylate in chronic obstructive lung disease and persistent hypoxemia. Controlled double-blind study with oral administration].
Wuttke R; von Wichert P
Respiration; 1985; 48(4):285-95. PubMed ID: 3936140
[TBL] [Abstract][Full Text] [Related]
9. A one year double blind follow-up of blood gas tensions and haemodynamics in almitrine bismesylate therapy.
Préfaut C; Bourgouin-Karaouni D; Ramonatxo M; Michel FB; Macabies J
Eur Respir J; 1988 Jan; 1(1):41-50. PubMed ID: 2896600
[TBL] [Abstract][Full Text] [Related]
10. Dose-response and pharmacokinetic study with almitrine bismesylate after single oral administrations in COPD patients.
Bury T; Jeannot JP; Ansquer JC; Radermecker M
Eur Respir J; 1989 Jan; 2(1):49-55. PubMed ID: 2495983
[TBL] [Abstract][Full Text] [Related]
11. [Almitrine in therapy of chronic obstructive respiratory tract diseases with hypoxemia--a clinical multicenter study comparing 2 dosages].
Nowak D; Wywiol A; Magnussen H
Pneumologie; 1998 Mar; 52(3):121-7. PubMed ID: 9564184
[TBL] [Abstract][Full Text] [Related]
12. Almitrine bismesylate and oxygen therapy in hypoxic cor pulmonale.
Evans TW; Tweney J; Waterhouse JC; Nichol J; Suggett AJ; Howard P
Thorax; 1990 Jan; 45(1):16-21. PubMed ID: 2108510
[TBL] [Abstract][Full Text] [Related]
13. A one-year double-blind placebo-controlled study of the efficacy and safety of almitrine bismesylate in hypoxic COLD patients. Monitoring progress status on 490 patients entered into the VIMS study before January 1st, 1984.
Ansquer JC
Eur J Respir Dis Suppl; 1986; 146():703-12. PubMed ID: 3536563
[TBL] [Abstract][Full Text] [Related]
14. Long-term effects of almitrine bismesylate in COPD patients with chronic hypoxaemia.
Sans-Torres J; Domingo C; Morón A; Rué M; Marín A
Respir Med; 2003 Jun; 97(6):599-605. PubMed ID: 12814142
[TBL] [Abstract][Full Text] [Related]
15. Double-blind placebo controlled clinical trial of almitrine bismesylate in patients with chronic respiratory insufficiency.
Bakran I; Vrhovac B; Stangl B; Tabori D; Ivicevic A; Todic V; Kandare F
Eur J Clin Pharmacol; 1990; 38(3):249-53. PubMed ID: 2187700
[TBL] [Abstract][Full Text] [Related]
16. Long term studies on almitrine bismesylate in COPD patients.
Bourgouin-Karaouni D; Mercier J; Prefaut C
Eur J Respir Dis Suppl; 1986; 146():695-701. PubMed ID: 3096767
[TBL] [Abstract][Full Text] [Related]
17. Effect of almitrine bismesylate on pulmonary vasoreactivity to hypoxia in chronic obstructive pulmonary disease.
Saadjian AY; Philip-Jöel FF; Barret A; Levy S; Arnaud AG
Eur Respir J; 1994 May; 7(5):862-8. PubMed ID: 8050541
[TBL] [Abstract][Full Text] [Related]
18. Vectarion International Multicentre Study (VIMS): a long term double blind placebo controlled trial in COLD patients.
Sadoul P
Eur J Respir Dis Suppl; 1983; 126():357-61. PubMed ID: 6373344
[TBL] [Abstract][Full Text] [Related]
19. [The first Italian clinical experience with almitrine bismesylate].
Grassi V; Bottino G; Blasi A; Grassi C
Rev Mal Respir; 1985; 2 Suppl 1():S53-60. PubMed ID: 2870548
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of almitrine bismesylate on oxygenation during wakefulness and sleep in chronic obstructive pulmonary disease.
Gothe B; Cherniack NS; Bachand RT; Szalkowski MB; Bianco KA
Am J Med; 1988 Mar; 84(3 Pt 1):436-44. PubMed ID: 2894764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
